Advertise on podcast: Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up, Cell Culture Innovation

Biotech founders often pour everything into building the “perfect” product only to realize their real customers have walked out the door. Chasing perfection can burn money and stall even the most promising CMC innovations. In this episode, David Brühlmann continues his conversation with biotech entrepreneur and investor John Bonham-Carter. John shares his insights on the realities of building and scaling successful biotools companies, from the challenges of fundraising and the importance of authentic storytelling, to knowing when to stop perfecting a product and start selling. Topics discussed: How fundraising is less about money and more about the story, team, and real commitment behind a startup (02:33)Practical advice for founders: obsess over the customer, not just the technology (07:14)The dangers of spreading yourself too thin as a startup founder and lessons from parenting applied to startups (07:09)Choosing business partners and collaborators whose skills complement your own—and making peace with imperfection (10:10)John’s approach to building teams and why accepting mediocrity in some areas can lead to collective excellence (11:16)The story behind John joining Stellion Biosystems, and what makes their cell counting technology different in the market (11:51)Using creative, low-budget tactics for visibility—why John chose a lizard mascot for Stellion Biosystems (15:19)Thoughts on when (if ever) to stop and the value of keeping multiple life and career doors open (17:26)John’s main takeaway: “Try everything”—professional advice drawn from experience (and Zootopia) (19:01)Smart insight: John leaves us with a simple yet powerful credo: “Try everything.” In biotech, that means embracing experimentation not just in the lab, but in business strategy, partnerships, hiring, and technology adoption. By collaborating, iterating, and listening closely to customers, you can grow, succeed, and—perhaps—build something that truly makes a difference. In a field where the only constant is change, remember: launch before you’re ready, find your people, and keep your story genuine. Some ideas are ahead of their time; a few people make a career of being early. This is part bioprocess history, part founder's playbook: why the best technology doesn't automatically win, how to move a conservative industry, and when to sell rather than scale. To go further on both the technology and the business behind it: Episodes 191 - 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas CastanEpisodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeEpisodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)Connect with John Bonham-Carter: Website: www.stellion-biosystems.com LinkedIn: www.linkedin.com/in/johnbc Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Biotech loves talk of disruptive technology, but few have repeatedly shifted the industry's direction. This episode of the Smart Biotech Scientist Podcast focuses on an idea once dismissed as a fool's game: process intensification through perfusion—now the backbone of leading biomanufacturing platforms. Meet John Bonham-Carter, a serial entrepreneur whose fingerprints are on some of biotech's most transformative tools. From putting the once-ignored ATF system and perfusion on the global stage to pushing intensified cell therapy bioprocessing with ERBI, John's story isn't about chasing the next big exit. Instead, it's about spotting unmet needs and building and selling biotools companies more than once. Topics discussed: The story behind the ATF system, and how John Bonham-Carter and his collaborators convinced a conservative industry to adopt perfusion (04:43)Early career influences, including family ties to bioprocess equipment manufacturing (05:03)Reflections on the biotech industry’s culture of collaboration and the dual motivation to deliver medicines and achieve commercial success (07:18)Realities of scaling a startup, trading income for equity, and the role of persistence in sales (09:34)Lessons learned from global travel and building professional networks in biotech (10:16)The importance of recognizing what drives different biotech companies to adopt new technology (12:25)The transition from ATF to co-founding Erbi, a bioprocessing startup focused on small-volume cell therapy (19:05)Strategic acquisitions: experiences of being acquired by Repligen and Merck Millipore (22:50)Advice for founders on whether to build a company for exit or long-term operation (23:07)The limits of leading with technology, and why customer understanding is critical to success (26:10)Smart insight: For founders, John Bonham-Carter offers practical guidance anchored in self-awareness. Should you build a company for the long haul or for acquisition? The answer: “There isn’t really a right answer...it is, what is the life you want to lead?” Some entrepreneurs thrive at the scale of ten-person teams and relish the handoff to a strategic acquirer. Others yearn to build and steer a 200-person enterprise. Regardless, serving customers and employees well, and being attuned to the market’s shifting demands, matter most. Exit opportunities arise from building value and strategic fit—not from fixating on selling out. Some ideas are ahead of their time; a few people make a career of being early. This is part bioprocess history, part founder's playbook: why the best technology doesn't automatically win, how to move a conservative industry, and when to sell rather than scale. To go further on both the technology and the business behind it: Episodes 191 - 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas CastanEpisodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeEpisodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)Connect with John Bonham-Carter: Website: www.stellion-biosystems.com LinkedIn: www.linkedin.com/in/johnbc Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

What if building a world-class biotech company didn’t require owning a single piece of manufacturing equipment or even a lab of your own? Most startups obsess over bricks, mortar, and stainless steel. Not Sandra Núñez. She’s challenging the status quo as CEO of Amela Biosciences by running a “virtual plant” model: zero in-house production, everything outsourced, and agility baked into every decision. It’s a bold experiment in redefining what a biotech company can look like. One that’s already delivering real, animal-free products to customers today. Topics discussed: Key considerations and pitfalls in tech transfer from academic labs to external CDMO partners (02:34)The reasoning behind choosing a virtual plant model with no in-house manufacturing (04:57)Criteria for selecting external manufacturing partners, including technical capabilities and cultural fit (06:28)Stakeholder communications and managing misconceptions about outsourced manufacturing (07:44)Process development challenges when scaling products for commercial use, including impurity profile and scalability of purification methods (08:53)Early preparations for future GMP manufacturing and building a foundation for regulatory compliance (11:20)The impact of regulatory shifts (like the FDA Modernization Act 2.0) on manufacturing strategy and product reproducibility (12:47)Hopes for the company’s future role in the transition to animal-free and regenerative medicine (14:19)Practical advice for startup founders considering a leap from corporate biotech to entrepreneurship (15:09)Reflections on the importance of addressing batch-to-batch variability and building reproducible systems (16:40)Smart insight: Don’t accept batch-to-batch variability. Reproducibility is non-negotiable. Batch-to-batch variability, whether in raw materials or process design, is a critical risk that forward-thinking should design out, not accept as inevitable. As Sandra concludes, reproducibility isn’t just a lab problem, it’s a company-building problem, one that shapes strategy, manufacturing partnerships, and regulatory success. Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory: Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt BakerEpisodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina BritoEpisodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria BaletEpisodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher LocherConnect with Sandra Núñez: Website: www.amelabiosciences.com Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch Sandra’s email: [email protected] Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Batch-to-batch variability isn’t just a minor annoyance in bioprocess development; it’s often a systemic design flaw hiding in plain sight. That’s the challenge Sandra Núñez, CEO of Amela Biosciences, set out to eliminate. Drawing on 15 years across Lonza, Medinova, Baxalta, and Biogen, she’s engineered a new generation of animal-free, recombinant protein matrices that promise researchers experimental consistency on demand. Topics discussed: The widespread issue of batch-to-batch variability and why Sandra argues it’s a design failure, not the norm (02:49)The mechanics and biological tunability of Amela’s engineered protein matrices, and how this technology works (06:34)How Amela’s recombinant protein bioinks differ from traditional animal-sourced extracts, enabling reproducibility (08:53)Manufacturing insights: why the proteins are relatively straightforward to produce for research use (12:05)Engaging with users to optimize and customize protein matrices for diverse tissue and assay applications (13:33)The creation and use of protein libraries for specific user requirements and the flexibility this provides (16:20)Definitions and roles of ‘bioinks’ in tissue modeling and 3D cell culture (16:52)Smart insight: Reproducibility remains the cornerstone of reliable science. With innovative platforms like Amela Biosciences’ engineered protein matrices, the future of tissue engineering and in vitro biology looks not just reliable, but radically empowering. If you’re striving for consistency, customizability, and cutting-edge technology in your workflows, the era of animal-free, batch-consistent bioinks has arrived. Here are four episodes that pick up the same threads: animal-free matrices, reproducibility by design, and building a biotech without a factory: Episodes 271 - 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt BakerEpisodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina BritoEpisodes 275 - 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria BaletEpisodes 279 - 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher LocherConnect with Sandra Núñez: Website: www.amelabiosciences.com Company LinkedIn: www.linkedin.com/company/amela-biosciences-ag Sandra’s LinkedIn: www.linkedin.com/in/sandra-nunez-ch Sandra’s email: [email protected] Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Manufacturability challenges in biotech are becoming more complex as therapies become more potent, formats diversify, and timelines compress across the industry. On this episode, David Brühlmann sits down with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. Sigma brings deep expertise in early-stage CMC decision-making and has guided countless programs—from upstart startups to established pipelines—through the traps and trade-offs of process development. Her ground-floor perspective spans in silico modeling, innovative cell line engineering, and the gritty realities of tech transfer. Key topics discussed: Practical advice for startups on selecting robust cell lines and avoiding long-term lock-in to problematic platforms (03:07)Managing risks in process development, such as high oxygen demand and filter loading, before tech transfer to manufacturing (04:47)The value of pressure testing bioprocesses at scale and identifying potential failure modes, including filter clogging and narrow feeding windows (07:41)Balancing speed, robustness, and regulatory expectations when advancing new molecules (09:23)How fast-tracking from transfection to IND is changing timelines, and the associated risks of accelerated development (09:54)Trends and caution in applying AI and in silico tools to protein and process modeling, and the limits of digital solutions (12:01)What first-time founders need to get right, including early analysis of molecular issues and careful cell line selection (15:48)Shifting modality trends—growing numbers of ADCs/XDCs, more complexity, and the move toward smaller scale and more potent molecules (16:55)The overarching lesson: invest early in the areas you cannot change later—especially cell line and understanding of molecule challenges (18:23)Smart insight: Startup founders often wonder which fires to fight first. Sigma’s advice: focus on deep molecular assessment and making informed, scalable cell line choices above all else. These are the “few things you cannot change later” and the investments that separate enduring programs from cautionary tales. This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent. Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Sigma Mostafa:  Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

A breakthrough in drug discovery can be derailed in an instant if manufacturability is left as an afterthought. Too many biotech programs hit bottlenecks at scale-up because key decisions in cell line and process development get kicked down the road. On the Smart Biotech Scientist Podcast, David Brühlmann spoke with Sigma Mostafa, Chief Scientific and Technology Officer at KBI Biopharma. She’s spent 25+ years converting early-stage discoveries into commercial biomanufacturing success and she’s adamant: manufacturability decisions belong at the candidate selection stage, not after. Topics discussed: Why manufacturability should be assessed at the candidate selection stage, not later (03:02)Sigma’s background in bringing math and biology together and her path into bioprocess engineering (04:18)The "art" and complexity of bioprocess development, especially with new molecule types (05:54)A case study of how switching cell lines revealed hidden manufacturability issues (07:33)Key properties affecting manufacturability, such as aggregation and thermal stability (10:10)Reasons companies delay manufacturability assessments—timing pressure, costs, and lack of early deep characterization (11:02)Why CMC should be integrated from day one and concerns with treating scalability as 'just' engineering (12:08)Critical decisions and pitfalls in cell line development, including robustness, media choices, and adapting after the master cell bank is made (12:48)Regulatory aspects of cell line development: demonstrating clonality, avoiding animal source materials, and documentation requirements (15:04)Smart insight: Manufacturability is not just a box for the CMC team. It’s a proactive mindset, to be embraced from day one. Early, cross-functional scrutiny—examining both molecule and cell line—preempts disasters during scale-up and accelerates timelines to market while minimizing costly surprises. This episode unpacks what that means in practice and where speed and robustness pull against each other. If it resonated, these conversations expand the picture: how to spot manufacturable candidates early, how in silico tools predict stability and aggregation before the lab, and which early CMC decisions quietly become permanent. Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Sigma Mostafa:  Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817 KBI website: https://www.kbibiopharma.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications. Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has made a career out of asking impossible questions about glycosylation, cell line selection, and the hidden machinery at work inside every productive cell. He’s moved beyond academic curiosity—translating discoveries into applications and even launching a company, Augment Biologics, that’s taking glycoengineering from theory to practice. Topics discussed: A proximity proteomics approach to identify supporting machinery for challenging-to-express proteins like rituximab (02:36)Findings from expressing the full human secretome in CHO cells, and the correlation between host cell gene expression and protein productivity (05:00)Clarifying when host cell characteristics matter more than the protein construct itself (05:46)Emerging evidence that protein sequence and structure influence glycosylation patterns (contrary to previous dogma) (06:49)Engineering point mutations to precisely tune glycan features for improved therapeutic efficacy (09:25)The vision and activities of Augment Biologics in custom glycosylation control for drug discovery (10:32)The importance and barriers to open data sharing in bioprocessing, and thoughts on overcoming them (11:11)The shifting landscape as technology advances and the need for high-quality, annotated data (13:54)If this got you thinking about the data already sitting in your freezer, and what it would take to actually use it, start here. These four conversations dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all. Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyEpisodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo JainEpisodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresIf you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty Connect with Nathan Lewis: Website: www.lewislab.uga.edu LinkedIn: www.linkedin.com/in/nathanelewis Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs. Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, and AI as a true scientific collaborator. Topics discussed: Rethinking the dogma: controlling protein glycosylation quality from the inside out, not just by bioprocess conditions (03:00)Nathan Lewis’s journey into science and bioprocessing, from unexpected college choices to pivotal advances in CHO cell engineering (05:12)The evolution of omics in bioprocessing: why actionable insights, not just big datasets, should be the goal (10:49)Strategic advice for structuring, annotating, and making old and new datasets ready for AI and LLM analysis (17:34)The balance between mechanistic and machine learning models—when each makes sense, and why hybrid modeling is gaining ground (22:20)The current and future role of digital twins in process development and why foundation models and data consortia matter for scalability (26:24)Smart insight: The real revolution isn’t in making new data, but in unlocking the value of what already exists. Advances in AI, hybrid modeling, and collaborative standards promise to turn decades-old data into a catalyst for innovation—enabling faster, smarter, and more reliable bioprocess development. If this got you thinking about the data already sitting in your freezer — and what it would take to actually use it — start here. These four dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all. Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyEpisodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo JainEpisodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro TorresIf you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty Connect with Nathan Lewis: Website: www.lewislab.uga.edu LinkedIn: www.linkedin.com/in/nathanelewis Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

“Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true. In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Hopkins postdoc project to a company with its first paying customer. In this episode: Common pushbacks and questions from industry regarding new cell line development technologies (03:18)Practical advice for resource-constrained startups developing cell lines, emphasizing efficiency and data quality over brute force automation (08:42)The role and value of DNA barcoding in screening and developing robust cell lines for therapeutics (08:56)Lessons learned from translating scientific innovation into a commercial product, including securing early support and customer trust (10:27)Insights on adapting messaging, leveraging feedback, and understanding market needs as part of the entrepreneurial process (13:52)Key differences between academic research and industry requirements for reliable, repeatable biotech tools (15:26)Kent’s most important takeaway for successful cell line development: focus on collecting the right data at the right scale for informed decisions (17:14)Smart insight: Translating innovations from academia to industry brings a new wave of challenges. Kent describes the “valley of death” separating a publishable prototype from a reliable, commercial-grade product. Academic success is often tied to novelty, publications, and grants, while industry demands repeatability, robustness, and consistent performance across labs and operators. Securing early champions and funding, iterating based on tough industry feedback, and building trust with initial partners all require resilience, and a willingness to pivot as needed. Feedback, even when harsh, becomes a “gift” that helps refine the product and business model. The secret is not a single breakthrough, but adaptability and relentless customer focus. If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up. Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea GoughEpisodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner NevillEpisodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiConnect with Kent Rapp: LinkedIn: www.linkedin.com/in/kent-rapp Biolinco website: www.biolinco.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them? Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies. This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of Biolinco, an entrepreneur who’s turning the classic approach to cell line development inside out. Drawing from his background in chemical engineering and his work in biomanufacturing at Johns Hopkins University, Kent teamed up with DNA barcoding experts to pioneer a new workflow: barcode every cell, pool them, and track their true performance in the environment that matters. Topics discussed: The pitfalls of brute-force screening in traditional cell line development (03:05)Kent’s background and how he was drawn to combine science, startups, and biomanufacturing (04:37)Overcoming discrepancies between small-scale and large-scale screening environments (08:30)How DNA barcoding allows for high-resolution, pooled clone screening (10:34)Sensitivity advantages of sequencing over plate-based detection (14:21)Methodology for tracking and recovering individual high-performing clones from pools (15:13)Impact on speed and workflow efficiency in cell line development (17:31)Regulatory and safety considerations related to DNA barcodes in cell lines (19:04)Smart insight: According to Kent, biotech as an industry has a tendency to "automate problems instead of solve them". Rather than addressing the root causes—like lack of meaningful measurements at relevant scales—companies often throw more robots and more plates at the issue, hoping brute force will finally yield the magical clone. But real process improvement requires a rethinking of what is being measured and how those insights are generated—not just a higher throughput of the same flawed assay. If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up. Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea GoughEpisodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner NevillEpisodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy AgrestiConnect with Kent Rapp: LinkedIn: www.linkedin.com/in/kent-rapp Biolinco website: www.biolinco.com Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because that protein sits on the particle surface, and a component nobody has filed before is the agency's problem regardless of what you call it. Proteolipid vehicles (PLVs), the platform Jitendra Kumar works on as Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, represent a novel frontier in drug delivery, Instead of being taken up into an endosome and having to escape it, a PLV fuses with the cell membrane and releases cargo straight into the cytosol. That opens targets and patient groups that liver-tropic lipid nanoparticles and viral vectors have struggled to reach, and it leaves Kumar building a regulatory file with nothing on the shelf to copy. Highlights from the episode: Strategies for communicating novel technology with regulatory agencies and ensuring robust science-driven submissions (02:34)What differentiates the analytical characterization of PLVs compared to standard recombinant proteins or antibodies (04:03)The development plan and regulatory pathway towards clinical and commercial approval for their lead leptin therapy (05:35)The evolving role of advanced techniques—such as cryo-EM—in supporting regulatory filings and product understanding (06:56)Jitendra Kumar's career journey: from agricultural research in India to protein science and neurodegeneration, and how these experiences inform current PLV technology development (09:00)Challenges of early diagnostics and product development in neurodegenerative diseases (14:29)Decision-making differences and focus in academic versus industry biotech research (15:32)Practical advice on the importance of honest technology assessment, building networks, and understanding both strengths and weaknesses (16:16)Smart insight: A persistent challenge for groundbreaking delivery systems is the lack of established regulatory playbooks. Jitendra Kumar laid out a science-first approach: let data do the talking, supported by rigorous GLP toxicology studies and transparent communication with agencies. Regulatory bodies like Health Canada are receptive to innovation, provided that sponsors demonstrate safety, efficacy, and scientific rationale for any deviation from standard criteria. If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper: Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed YoussefEpisodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark MelvilleConnect with Jitendra Kumar: LinkedIn: www.linkedin.com/in/jkumar2Email: [email protected]: www.entospharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all? Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does. Key topics discussed: Jitendra’s career background in structural biology and journey to Entos Pharmaceuticals (03:18)The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55)Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27)The FAST protein platform: origins, function, and advantages for drug delivery (07:56)Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55)Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21)Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23)Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12)Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31)Balancing process robustness with speed in new biotech ventures (16:02)The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15)Smart insight: Jitendra’s takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both. If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper: Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed YoussefEpisodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark MelvilleConnect with Jitendra Kumar: LinkedIn: www.linkedin.com/in/jkumar2Email: [email protected]: www.entospharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here Support the show

For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could democratize access to advanced therapies and open entirely new doors for oral, topical, and even global vaccine delivery. This week, David Brühlmann welcomes Christopher Locher, CEO and Co-founder of Versatope Therapeutics. Christopher has shaped the translation of novel vesicle technology from idea to clinical pipeline, navigating both the science and the unstructured realm of first-in-class GMP manufacturing. Topics discussed: Tackling GMP manufacturing challenges and analytics development from scratch (00:34)Deciding what to outsource vs. insource as a small biotech, and the value of a robust tech transfer process (02:25)Perspectives on partnering with CDMOs versus managing manufacturing and analytics in-house (02:40)Geographic expansion goals and considerations for delivering low-cost biologics in underserved markets (04:26)Differentiators of Versatope’s platform—endotoxin-free processes and non-pathogenic strains (05:05)Key advice on critical quality attributes and early regulatory planning for Phase 1 readiness (06:19)Lessons learned as a biotech founder—getting support, leveraging networks, and planning cost-effectively (07:57)Understanding end users, leveraging I-Corps™, and customer discovery in early product development (09:04)The science and promise of engineered nanovesicles: delivery routes, biological origins, and research applications (10:12)Business models for platform out-licensing and potential for co-development partnerships (12:58)Practical takeaways for scientists: setting "good enough" standards and focusing on lean, regulatory-aligned development (13:28)Smart insight: Christopher is honest about his blind spots, learning on the fly from CMC consultants, and the practical importance of “good enough” regulatory solutions delivers sharp advice for anyone charting the long road from discovery to human trials. Think monoclonal analytics, batch consistency, and the art of prioritization, all from someone who’s made it work with a small team and limited resources If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients. Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen MairhoferEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric MoyalConnect with Christopher Locher: Website: www.versatope.com LinkedIn: www.linkedin.com/in/christopher-locher-biotech Support the show

What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines? While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice. Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation. Topics discussed: How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39)The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17)Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38)Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28)Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53)Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47)Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21)Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53)Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30)The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12)Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech. If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients. Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen MairhoferEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric MoyalConnect with Christopher Locher: Website: www.versatope.com LinkedIn: www.linkedin.com/in/christopher-locher-biotech Support the show

How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts. Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning. Topics covered: Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35)Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07)Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34)Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42)Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26)The importance of understanding basic statistics before relying on AI-generated models (15:22)A stepwise summary for deploying digital modeling effectively in biotech (16:01)Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number. Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny. Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValEpisodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyConnect with Ignasi Bofarull-Manzano: LinkedIn: www.linkedin.com/in/ignasi-bofarull Körber Pharma website: www.koerber-pharma.com Support the show